Abstract 155P
Background
Chemotherapy currently serves as the cornerstone for treating metastatic pancreatic cancer (mPC). Nevertheless, the effectiveness of chemotherapy have yet to fully align with the demands and preferences of patients. There is an urgent necessity to delve into novel treatment avenues. Therefore, it is worth to assess the clinical value of combination of all three treatments. This study aims to evaluate the preliminary effectiveness and safety of penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) for mPC.
Methods
We conducted a phase Ⅱ prospective, single-arm, multicenter study involving first-line patients with histologically or cytologically confirmed mPC. Patients received penpulimab (200mg, IV, D1) and Anlotinib (12mg, P.O, QD, D1-14), in addition to nab-paclitaxel (125mg/m2, I.V, D1,8) and gemcitabine (1.0g/m2, I.V, D1,8), administered over a 21-day treatment cycle. The primary endpoints included the objective response rate (ORR) and disease control rate (DCR), while secondary endpoints encompassed Overall Survival (OS) (median), Progression-free Survival (PFS) (median), and safety.
Results
Between June 2022 and August 2023, 66 patients were enrolled. The longest treatment duration observed was 17 months. Out of these, 65 patients were eligible for response evaluation. The best response, indicated by the ORR, was recorded at 43% (28/65) (95%CI, 30.8-56.0), with 28 patients achieving partial response (PR). Notably, DCR stood at an impressive 95% (62/65) (95%CI, 87.1-99.0). The median PFS was calculated as 8.7 months. Grade 3 treatment-related adverse events (TRAEs) were reported in 39% patients (26/66). In prespecified exploratory transcriptomic biomarkers analysis, significantly higher expression of IFN-γ, T cell recruiting and Th17 recruiting scores were detected in CR/PR patients compared with SD/PD patients.
Conclusions
PAAG as first-line treatment demonstrated a promising efficacy and manageable AEs for mPC. Biomarkers identified in this study possessed the potential to guide the precise clinical application of PAAG.
Clinical trial identification
NCT05493995.
Editorial acknowledgement
Legal entity responsible for the study
Juan Du.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract